More than 20.000 participants are expected to attend the 2010 AACC/Clinical Lab Expo, making it a unique event for showcasing the company’s forthcoming NGAL clinical chemistry test.

Booth

BioPorto Diagnostics will be at booth 6301 on all congress days. Members of the sales and marketing team and management will be available for discussions concerning licensing opportunities, partnering and distribution rights. Please refer to the contact details below to make an appointment.

Poster presentations

BioPorto Diagnostics is presenting three scientific posters on NGAL at the meeting:

Poster No. A-18 - Evaluation of newly developed ELISAs for rat, mouse, dog and pig NGAL

Tuesday, July 27, 10:00 am – 12:30 pm / Animal Clinical Chemistry

Poster No. B-167 - Evaluation of a fully automated NGAL particle-enhanced turbidimetric test

Tuesday, July 27, 2:00 pm – 4:30 pm / Proteins/Enzymes

Poster No. C-33 - Urinary and plasma NGAL levels reflect the severity of acute kidney injury

Wednesday, July 28, 10:00 am – 12:30 pm / Clinical Studies/Outcomes

NGAL and The NGAL Test

NGAL is a novel biomarker for diagnosing acute kidney injury (AKI). The key advantage of NGAL is that it responds earlier than other renal status markers and has a proportionate response to injury.

The NGAL Test will be available for a wide range of clinical chemistry analyzers and will be launched in the beginning of 2011. The NGAL Test will be able to determine NGAL levels in both urine and plasma within a standard routine timeframe.

For more information or to set up an appointment, please contact:

Klaus Boberg Pedersen, Human Diagnostics Product Manager, kbp@bioporto.com

Trine Overgaard Østerbye, Sales and Marketing Manager, toe@bioporto.com

Ishan Gupta, Business Development Manager, Sales, ig@bioporto.com

For further information on the event: http://www.aacc.org/events/2010am/pages/default.aspx